- Company secures ‘CIITA Control Technology’ to mitigate immune rejection in allogeneic 바카라사이트 소닉 therapy products
- Korea-Canada co-development secures full (100%) patent rights
[by Jin, Yu Jeong] GC 바카라사이트 소닉 announced on February 24 that it has completed patent registration in Korea and Japan for a core technology central to the development of next-generation 바카라사이트 소닉 and gene therapies.
The patented technology involves regulation of the Class II Major Histocompatibility Complex (MHC) Transcription Activator (CIITA), a pivotal gene that governs immune rejection responses.
In general, allogeneic cell therapies derived from donor cells are inherently limited by the risk of immune rejection, as the recipient’s immune system recognizes the transplanted cells as foreign and mounts an immune response against them. In this context, GC Cell has secured a foundational technology designed to mitigate immune rejection by modulating this gene, thereby reducing immune system recognition.
According to GC 바카라사이트 소닉, the significance of this technology lies in its ability to generate hypoimmune 바카라사이트 소닉s through a relatively streamlined approach, without requiring the complex, simultaneous editing of multiple genes. The company further explained that this platform is not confined to a specific 바카라사이트 소닉 type or therapeutic indication and can be broadly applied across diverse 바카라사이트 소닉 therapy modalities, thereby offering a wide range of applications.
Furthermore, GC 바카라사이트 소닉 announced that it has secured intellectual property rights not only to the manufacturing process employing various gene-editing tools, but also to the engineered 바카라사이트 소닉s generated through this technology. This is expected to strengthen its competitiveness in the future commercialization of 바카라사이트 소닉 therapy products.
"It is particularly meaningful that we have secured the outcomes of our joint research with a global partner as our own intellectual property (IP). On the basis of this patent, we will continue to reinforce our technological competitiveness in the global cell therapy market," said Won Sung-yong, CEO of GC Cell.
This achievement was realized through collaboration with Feldan Therapeutics of Canada under the ‘Korea-Canada International Joint Technology Development Project,’ administered by the Korea Institute for Advancement of Technology (KIAT). Notwithstanding the joint research framework, GC Cell retains full (100%) ownership of the patent rights.